Generics' High Court Win Opens New Battleground With Pharmas

Law360, New York (April 17, 2012, 10:39 PM EDT) -- The U.S. Supreme Court's decision Tuesday allowing Caraco Pharmaceutical Laboratories Ltd. to challenge as overbroad Novo Nordisk A/S's use code for a patent covering diabetes drug Prandin opens the door to an influx of litigation between generics and brand-name drugmakers, but it remains to be seen just how broad the use codes can be, attorneys say.

The justices unanimously rejected the Federal Circuit's narrow reading of a provision of the Hatch-Waxman Act that set up a counterclaim allowing generics makers to challenge the patent information that...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.